JB Pharma slashes price of critical Heart Failure medicine AZMARDA (Sacubitril-Valsartan) by nearly 50 percent Ruchika Sharma5 Dec 2022 2:37 PM IST"This move by JB will not only help reduce the cost of treatment but will also help enhance the productive years of patients and their quality of...
Sacubitril/Valsartan may reduce mitral regurgitation in HFrEF, eliminating need for interventions Medha Baranwal13 Oct 2022 9:00 AM ISTUSA: The severity of mitral regurgitation (MR) in patients with heart failure with reduced ejection fraction (HFrEF) could be reduced by the use of...
Even lower doses of Sacubitril/valsartan suffice for improving outcomes in patients with HFrEF Jacinthlyn Sylvia12 Oct 2022 11:00 AM ISTAccording to a post hoc analysis of PROVE-HF, patients of heart failure who could not reach target dose of angiotensin receptor/neprilysin inhibitor...
Replace ACE inhibitors with sacubitril/valsartan once symptomatic HF develops in MI: insight from Paradise MI Dr. Kamal Kant Kohli30 Aug 2022 11:00 AM ISTPost hoc analysis of Paradise MI Trial has provided new insights on sacubitril/valsartan in myocardial infarction in a session in a Hot Line session...
Sacubitril, valsartan combo safe for HFpEF, not likely to cause cognitive decline Dr. Kamal Kant Kohli29 Aug 2022 10:30 AM ISTAccording to a new study, administration of combination of sacubitril/valsartan (Entresto) for heart failure with moderately reduced or preserved left...
Sacubitril/valsartan vs Enalapril in acute heart failure Dr. Nandita Mohan17 Aug 2022 9:15 AM ISTA recent study compared the safety and efficacy of valsartan/sacubitril (angiotensin receptor neprilysin inhibitor [ARNI]) against enalapril...
Managing heart failure with sacubitril-valsartan: Why ARNIs stand out? dr. Abhimanyu Uppal30 July 2022 11:18 AM ISTHeart failure (HF) is a major economic and health burden worldwide, characterized by the presence of dyspnea or limited exertion due to impaired...
JBCPL gets trademark assignment of HF drug Azmarda from Novartis for Rs 246 crores Ruchika Sharma4 April 2022 11:22 AM ISTMumbai: JB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda...
Dr Reddy's Labs, Novartis ink pact for cardiovascular brand Cidmus Ruchika Sharma2 April 2022 12:03 PM ISTUnder the agreement, Dr Reddy's will be assigned and transferred the Cidmus trademark in India from Novartis AG for a consideration of USD 61 Million
Sacubitril-valsartan not tied to lower death risk versus ramipril in acute myocardial infarction: Study Medha Baranwal4 Dec 2021 9:00 AM ISTUSA: A recent study suggests that in patients with acute myocardial infarction, sacubitril-valsartan did not significantly lower death risk from...
Sacubitril/valsartan decreases plasma NT-proBNP in HF patients with preserved ejection fraction: JAMA Medha Baranwal3 Dec 2021 9:00 AM ISTGermany: Sacubitril/valsartan significantly decreased plasma NT-proBNP levels at 12 weeks compared with standard medical therapies in patients with...
Sacubitril/Valsartan does not best valsartan in patients with advanced heart failure: LIFE Trial Medha Baranwal24 Nov 2021 9:00 AM ISTThe trial found no significant improvements with the combination drug when compared with valsartan in terms of the primary endpoint.USA:...
